Ampyra and Heavy or prolong menstrual bleeding - a phase IV clinical study of FDA data

Summary:

Heavy or prolong menstrual bleeding is found among people who take Ampyra, especially for people who are 40-49 old, have been taking the drug for 1 - 6 months.

The phase IV clinical study analyzes which people take Ampyra and have Heavy or prolong menstrual bleeding. It is created by eHealthMe based on reports of 75,087 people who have side effects when taking Ampyra from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Feb, 07, 2023

75,087 people reported to have side effects when taking Ampyra.
Among them, 32 people (0.04%) have Heavy or prolong menstrual bleeding.

What is Ampyra?

Ampyra has active ingredients of dalfampridine. It is often used in multiple sclerosis. eHealthMe is studying from 75,229 Ampyra users for its effectiveness, alternative drugs and more.

What is Heavy or prolong menstrual bleeding?

Heavy or prolong menstrual bleeding is found to be associated with 1,778 drugs and 1,178 conditions by eHealthMe.

Number of Ampyra and Heavy or prolong menstrual bleeding reports submitted per year:

Could Ampyra cause Heavy or prolong menstrual bleeding?

Time on Ampyra when people have Heavy or prolong menstrual bleeding *:

Age of people who have Heavy or prolong menstrual bleeding when taking Ampyra *:

Common drugs people take besides Ampyra *:

Common side effects people have besides Heavy or prolong menstrual bleeding *:

Fatigue (feeling of tiredness): 12 people, 37.50%
Skin Blushing/flushing (a sudden reddening of the face, neck): 11 people, 34.38%
Depression: 10 people, 31.25%
Gait Disturbance: 10 people, 31.25%
Insomnia (sleeplessness): 9 people, 28.12%
Headache (pain in head): 9 people, 28.12%
Memory Loss: 9 people, 28.12%
Influenza Like Illness: 9 people, 28.12%
Urinary Tract Infection: 8 people, 25.00%
Weakness: 8 people, 25.00%

Common conditions people have *:

Gait Disturbance: 15 people, 46.88%
Pain In Extremity: 5 people, 15.62%
Multiple Sclerosis Relapse (reoccurrence of a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 4 people, 12.50%
Cognitive Disorder (mental health disorders affects learning, memory, perception, and problem solving): 4 people, 12.50%
Pulmonary Embolism (blockage of the main artery of the lung): 1 person, 3.12%
Pain: 1 person, 3.12%
Muscle Spasms (muscle contraction): 1 person, 3.12%
Mobility Decreased (ability to move is reduced): 1 person, 3.12%
Joint Pain: 1 person, 3.12%
High Blood Pressure: 1 person, 3.12%

* Approximation only. Some reports may have incomplete information.

Do you take Ampyra and have Heavy or prolong menstrual bleeding?

Check whether Heavy or prolong menstrual bleeding is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Coskun M, Adak I, "Excessive and frequent menstrual bleeding with methylphenidate in an adolescent girl with attention-deficit hyperactivity disorder", Journal of clinical psychopharmacology, 2017 Oct .

Related studies

How severe was Heavy or prolong menstrual bleeding and when was it recovered:

Heavy or prolong menstrual bleeding in Ampyra

Expand to all the drugs that have ingredients of dalfampridine:

Heavy or prolong menstrual bleeding and drugs with ingredients of dalfampridine (17 reports)

Alternative drugs to, pros and cons of Ampyra:

Ampyra (75,229 reports)

Common Ampyra side effects:

Drug ineffective: 8,776 reports
Weakness: 6,572 reports
Fatigue (feeling of tiredness): 6,118 reports
Urinary tract infection: 4,633 reports

Browse all side effects of Ampyra:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Heavy or prolong menstrual bleeding treatments and more:

Heavy or prolong menstrual bleeding (38,011 reports)

COVID vaccines that are related to Heavy or prolong menstrual bleeding:

Common drugs associated with Heavy or prolong menstrual bleeding:

All the drugs that are associated with Heavy or prolong menstrual bleeding:

Heavy or prolong menstrual bleeding (1,778 drugs)

Common conditions associated with Heavy or prolong menstrual bleeding:

All the conditions that are associated with Heavy or prolong menstrual bleeding:

Heavy or prolong menstrual bleeding (1,178 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on dalfampridine (the active ingredients of Ampyra) and Ampyra (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.